ArticleClinical proteomics2014
Deciphering the ovarian cancer ascites fluid peptidome.
Article in Clinical proteomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Identification of Proteins Associated with Ovarian Cancer Chemotherapy Resistance Using MALDI-MSI.International journal of molecular sciences · 2025Article
- A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer.Cancers · 2022Article
- Applications of Proteomics in Ovarian Cancer: Dawn of a New Era.Proteomes · 2022Review
- Importance of Potential New Biomarkers in Patient with Serouse Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Ascites from Ovarian Cancer Induces Novel Fucosylated Proteins.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2019Article
- Prognostic values of transketolase family genes in ovarian cancer.Oncology letters · 2019Article
- Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.Immunogenetics · 2019Review
- Peptidome profiling dataset of ovarian cancer and non-cancer proximal fluids: Ascites and blood sera.Data in brief · 2019Article
- Significance of the Differential Peptidome in Multidrug-Resistant Tuberculosis.BioMed research international · 2019Article
- Multi-platform Affinity Proteomics Identify Proteins Linked to Metastasis and Immune Suppression in Ovarian Cancer Plasma.Frontiers in oncology · 2019Article
- The plasma peptides of breast versus ovarian cancer.Clinical proteomics · 2019Article
- Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment.Theranostics · 2019Article
- The plasma peptides of ovarian cancer.Clinical proteomics · 2018Article
- Vitronectin in the ascites of human ovarian carcinoma acts as a potent chemoattractant for ovarian carcinoma: Implication for metastasis by cancer stem cells.Journal of cancer stem cell research · 2016Article
- Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.Clinical & experimental metastasis · 2015Article
- Proteomics in cancer biomarkers discovery: challenges and applications.Disease markers · 2015Review
- Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.Proteomics. Clinical applications · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConventional proteomic approaches have thus far been unable to identify novel serum biomarkers for ovarian cancer that are more sensitive and specific than the current clinically used marker, CA-125. Because endogenous peptides are smaller and may enter the circulation more easily than proteins, a focus on the low-molecular-weight region may reveal novel biomarkers with enhanced sensitivity and specificity. In this study, we deciphered the peptidome of ascites fluid from 3 ovarian cancer patients and 3 benign individuals (ascites fluid from patients with liver cirrhosis).
resultsFollowing ultrafiltration of the ascites fluids to remove larger proteins, each filtrate was subjected to solid phase extraction and fractionated using strong cation exchange chromatography. The resultant fractions were analyzed using an Orbitrap mass spectrometer. We identified over 2000 unique endogenous peptides derived from 259 proteins. We then catalogued over 777 peptides that were found only in ovarian cancer ascites. Our list of peptides found in ovarian cancer specimens includes fragments derived from the proteins vitronectin, transketolase and haptoglobin.
conclusionsPeptidomics may uncover previously undiscovered disease-specific endogenous peptides that warrant further investigation as biomarkers for ovarian cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.